Xtacy Therapeutics Reports Filing Delay and MCTO

Xtacy Therapeutics Corp. (TSE:XTCY) has released an update.

Xtacy Therapeutics Corp. has updated stakeholders on the status of their previously announced Management Cease Trade Order (MCTO), confirming the delay in filing their annual financial documents for the year ended September 30, 2023. The company has been granted the MCTO by the British Columbia Securities Commission and is committed to providing bi-weekly updates until the required documents are filed. Xtacy’s management is actively working with auditors to resolve the issue and comply with regulatory guidelines.

For further insights into TSE:XTCY stock, check out TipRanks’ Stock Analysis page.